The 2028 Rate Cycle Is the Trade Nobody Priced: Part D's 50% Premium Shock and a Blue Sweep Pull in Opposite Directions

The 2027 Part D repricing is arithmetic, not sentiment. The Inflation Reduction Act's redesign raised what plans owe for the basic benefit, and CMS capped the government's share of the premium at 6% growth — $38.99 to $41.33. The gap between a 25% cost increase and a 6% premium cap landed on deductibles, coinsurance and enrollee premiums, and it landed hardest on the people least able to absorb it.

Two independent estimates land on the same dollar: KFF projects the average stand-alone premium at $51 and the American Action Forum at $51.47. The market is shrinking to match — 32 sponsors exited stand-alone Part D for 2027, 26 more consolidated into 12 plans, and the number of low-income benchmark plans fell from 88 to 63. Beneficiaries facing an increase number 10.4 million, and 2.4 million of them face a monthly jump of $50 or more.

Medicare Advantage drug plans are now the cheapest place in the market for a senior to land, which is precisely why the cost does not disappear — it changes owner. The average MA-PD premium is $9 a month against $51 for a stand-alone plan, so the premium shock shifts drug cost from stand-alone plans into Medicare Advantage, where CMS sets most of the price.

That gap is the whole bid debate, and it is why the 2028 file is the one to watch. CMS's own 2027 analysis stopped the Premium Stabilization Demonstration at the end of 2026, having concluded that sponsors had enough experience under the redesigned benefit to support their assumptions. The 2028 bid is therefore the first one written with no shock absorber: the cost of the benefit is known, the 6% cap still binds, and the June 2027 filing date is set. CMS closed its 2027 Part D formulary window on June 1, 2026; the 2028 bid lands in the same window a year later.

Medicaid is the mirror image of Part D. The 2025 reconciliation law cut $911 billion from federal Medicaid spending through 2034 and required 44 states to operate work requirements by January 1, 2027, and the enrollment base has already fallen 5.1 million in twelve months. The arithmetic that hurts Medicaid managed care is not the loss of members but healthy members leaving faster than sick members do.

The reason 2027 rates are catching up with 2027 costs is an instrument most investors have never heard of: the state directed payment. States have used uniform-increase directed payments to top up Medicaid capitation rates without the political fight of a rate cut or a tax increase. CMS has now proposed to remove that instrument for rating periods beginning on or after January 1, 2028, which means the states setting 2028 rates during 2027 will do so without the plug they used for the last two cycles.

This is the collision that has not been priced. The 2027 Medicaid rate cycle is the first to absorb work requirements, and it is protected by a tool that disappears on January 1, 2028. The 2028 cycle is the first to run without that tool, against a book that has already lost 5.1 million people and a cost base where the remaining members skew sicker. Both files are written in the same window, by the same management teams, in the middle of a Congress that has just changed parties.

Democrats took control of both chambers on November 3, and their first stated priority is the money: restoring lapsed ACA subsidies and reversing the 2025 Medicaid cuts, with the incoming majority saying it will move early in 2027. That puts expansion back on the table in ten states, and it puts the federal matching rate back in play for the forty-one states plus the District of Columbia that have already expanded.

The sequencing is what makes this tradeable. The market is currently paying for the statute: managed care is being valued on 2027 rates written under the 2025 law, and the stocks have already absorbed a $1.50 per-share Florida implementation loss at Molina Healthcare and an 810,500-member Medicaid decline at Centene. The 2028 files are priced off that base. If Congress restores funding and repeals work requirements, the cash arrives as a 2029 rate event and the 2028 option is free. If nothing passes, the 2028 rates get set against a smaller, sicker book with the directed-payment plug removed.

The cost of a Medicaid cut does not stop at the insurer. It shows up on hospital balance sheets as uncompensated care, and the Congressional Budget Office's projection of 7.5 million more uninsured by 2034 is the first half of that bill. The precedent from the ACA is the mirror image: when expansion arrived, hospital charity care and bad debt fell $8.6 billion, or 23%, between 2013 and 2015.

Pharmacy benefit managers sit between the plans and the drug supply chain, and they are paid per script rather than per premium. That makes the 2027 shock a mix event rather than a volume collapse: scripts do not vanish when premiums rise, they migrate from stand-alone PDP books into Medicare Advantage books where the contracts and rate cards differ.